{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:27:47Z","timestamp":1785796067832,"version":"3.56.0"},"reference-count":19,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"3","license":[{"start":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T00:00:00Z","timestamp":1569283200000},"content-version":"vor","delay-in-days":511,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction:<\/jats:title>\n                  <jats:p>Antipsychotics are used off label to treat behavioral and psychological symptoms of dementia (BPSD). Due to the emerging data of selective serotonin reuptake inhibitors (SSRIs) for treatment of BPSD, clinicians may choose to use this medication class instead of antipsychotics when pharmacologic therapy is necessary. The objective of this study was to evaluate the prevalence of antipsychotic discontinuation 6 months after SSRI initiation for the treatment of BPSD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Patients with Alzheimer dementia who were prescribed an antipsychotic and later prescribed an SSRI for BPSD during January 1, 2009, through December 30, 2014, were studied. Exclusion criteria included (1) a dementia diagnosis besides Alzheimer; (2) scheduled benzodiazepines, mood stabilizers, or non-SSRI antidepressant use during the study period; (3) diagnoses of bipolar or psychotic disorders; and (4) diagnosis of delirium during the study period. Patients' age, sex, race, and functional assessment of staging for Alzheimer disease scores were collected. The names, doses, and stop dates of SSRIs and antipsychotics were also recorded.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Thirty-six patients were included in the analyses. Overall, antipsychotic use was reduced in 11 patients (30.6%). Ten patients (27.8%) discontinued the antipsychotic, and 1 additional patient had a reduction in dose. When comparing specific SSRIs, 8 (72%) responders were prescribed citalopram, and 15 (60%) nonresponders were prescribed sertraline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion:<\/jats:title>\n                  <jats:p>Approximately 30% of patients with Alzheimer dementia who were prescribed antipsychotics for BPSD were able to discontinue the medication or had a dose reduction after starting SSRI therapy. Most SSRI responders were prescribed citalopram.<\/jats:p>\n               <\/jats:sec>","DOI":"10.9740\/mhc.2018.05.122","type":"journal-article","created":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T12:34:30Z","timestamp":1525178070000},"page":"122-126","source":"Crossref","is-referenced-by-count":5,"title":["Antipsychotic discontinuation after the initiation of selective serotonin reuptake inhibitors therapy for the treatment of behavioral and psychological symptoms associated with dementia"],"prefix":"10.9740","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6907-1996","authenticated-orcid":false,"given":"Monica","family":"Mathys","sequence":"first","affiliation":[{"name":"(Corresponding author) Associate Professor of Pharmacy Practice, Clinical Pharmacy Specialist \u2013 Mental Health, Texas Tech University Health Sciences Center, Veterans Affairs North Texas Health Care System, Dallas, Texas, monica.mathys@ttuhsc.edu"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-413X","authenticated-orcid":false,"given":"Steven","family":"Fang","sequence":"first","affiliation":[{"name":"PharmD Student, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4290-4334","authenticated-orcid":false,"given":"Jini","family":"John","sequence":"first","affiliation":[{"name":"PharmD Student, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0332-832X","authenticated-orcid":false,"given":"Jasmine","family":"Carter","sequence":"first","affiliation":[{"name":"PharmD Student, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"issue":"5","key":"2020060307274017900_i2168-9709-8-3-122-b01","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jalz.2011.05.2410","article-title":"Neuropsychiatric symptoms in Alzheimer's disease","volume":"7","author":"Lyketsos","year":"2011","journal-title":"Alzheimers Dement"},{"key":"2020060307274017900_i2168-9709-8-3-122-b02","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fneur.2012.00073","article-title":"Behavioral and psychological symptoms of dementia","volume":"3","author":"Cerejeira","year":"2012","journal-title":"Front Neurol"},{"issue":"6","key":"2020060307274017900_i2168-9709-8-3-122-b03","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1179\/acb.2007.062","article-title":"Clustering of behavioural and psychological symptoms in dementia (BPSD): a European Alzheimer's disease consortium (EADC) study","volume":"62","author":"Petrovic","year":"2007","journal-title":"Acta Clin Belg"},{"key":"2020060307274017900_i2168-9709-8-3-122-b04","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/PRBM.S44775","article-title":"Dealing with behavioral and psychological symptoms of dementia: a general overview","volume":"8","author":"Azermai","year":"2015","journal-title":"Psychol Res Behav Manag"},{"issue":"15","key":"2020060307274017900_i2168-9709-8-3-122-b05","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"JAMA"},{"issue":"7489","key":"2020060307274017900_i2168-9709-8-3-122-b06","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1136\/bmj.38330.470486.8F","article-title":"Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study","volume":"330","author":"Gill","year":"2005","journal-title":"BMJ"},{"issue":"22","key":"2020060307274017900_i2168-9709-8-3-122-b07","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa052827","article-title":"Risk of death in elderly users of conventional vs. atypical antipsychotic medications","volume":"353","author":"Wang","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"2020060307274017900_i2168-9709-8-3-122-b08","doi-asserted-by":"publisher","first-page":"e001666","DOI":"10.1161\/JAHA.114.001666","article-title":"Association of selected antipsychotic agents with major adverse cardiovascular events and noncardiovascular mortality in elderly persons","volume":"4","author":"Sahlberg","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"7496","key":"2020060307274017900_i2168-9709-8-3-122-b09","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","article-title":"Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial","volume":"330","author":"Ballard","year":"2005","journal-title":"BMJ"},{"issue":"8","key":"2020060307274017900_i2168-9709-8-3-122-b10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1176\/appi.ajp.2011.08121844","article-title":"Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD","volume":"168","author":"Vigen","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"4","key":"2020060307274017900_i2168-9709-8-3-122-b11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/gps.1885","article-title":"Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis","volume":"23","author":"Deberdt","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"issue":"11","key":"2020060307274017900_i2168-9709-8-3-122-b12","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/gps.1397","article-title":"Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia","volume":"20","author":"Kennedy","year":"2005","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"2020060307274017900_i2168-9709-8-3-122-b13","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1176\/appi.ajp.2008.08081218","article-title":"Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study","volume":"166","author":"Zheng","year":"2009","journal-title":"Am J Psychiatry"},{"key":"2020060307274017900_i2168-9709-8-3-122-b14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0167-4943(01)00135-2","article-title":"Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia","volume":"33","author":"Gaber","year":"2001","journal-title":"Arch Gerontol Geriatr Suppl"},{"issue":"1","key":"2020060307274017900_i2168-9709-8-3-122-b15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/gps.998","article-title":"A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil","volume":"19","author":"Finkel","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"2020060307274017900_i2168-9709-8-3-122-b16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1176\/appi.ajp.159.3.460","article-title":"Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients","volume":"159","author":"Pollock","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"11","key":"2020060307274017900_i2168-9709-8-3-122-b17","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1097\/JGP.0b013e3180cc1ff5","article-title":"A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia","volume":"15","author":"Pollock","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"issue":"7","key":"2020060307274017900_i2168-9709-8-3-122-b18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"JAMA"},{"issue":"9","key":"2020060307274017900_i2168-9709-8-3-122-b19","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1017\/S1041610211000743","article-title":"Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study","volume":"23","author":"Barak","year":"2011","journal-title":"Int Psychogeriatr"}],"container-title":["Mental Health Clinician"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/8\/3\/122\/2182565\/mhc_2018_05_122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/8\/3\/122\/2182565\/mhc_2018_05_122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T16:20:21Z","timestamp":1731687621000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/8\/3\/article-p122.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,1]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5,1]]}},"URL":"https:\/\/doi.org\/10.9740\/mhc.2018.05.122","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,1]]}}}